Scarica l'app Stockscreener
26.29
2.18%
0.56
Dopo l'orario di chiusura:
26.29
Precedente Chiudi:
$25.73
Aprire:
$25.74
Volume 24 ore:
932.83K
Relative Volume:
1.44
Capitalizzazione di mercato:
$1.13B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
18.13
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
+9.59%
1M Prestazione:
+10.18%
6M Prestazione:
+7.53%
1 anno Prestazione:
+32.78%
Intervallo 1D:
$25.16
$26.46
Intervallo di 1 settimana:
$23.63
$26.46
Portata 52W:
$18.17
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
26.29 | 1.11B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
(PCRX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Barclays Initiates Coverage of Pacira BioSciences (PCRX) with Equal-Weight Recommendation - Nasdaq
Pacira BioSciences (PCRX): Barclays Initiates Coverage with Equa - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Barclays - MarketBeat
102,668 Shares in Pacira BioSciences, Inc. $PCRX Bought by WINTON GROUP Ltd - MarketBeat
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
EV Market: Will Pacira BioSciences Inc. stock maintain momentum in 20252025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ
Will Pacira BioSciences Inc. (82P) stock rise with strong economyQuarterly Trade Report & Real-Time Volume Analysis Alerts - Newser
How Investors Are Reacting To Pacira BioSciences (PCRX) Spine Pain Trial Win And New FDA Clearance - Sahm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Can Pacira BioSciences Inc. (82P) stock surprise with quarterly resultsJuly 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Is Pacira BioSciences Inc. (82P) stock among top earnings plays2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - Newser
Can Pacira BioSciences Inc. stock deliver surprise earnings beatWeekly Market Summary & Real-Time Price Movement Reports - Newser
Pacira Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Pacira BioSciences (PCRX) Awards Inducement Grants to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences (Nasdaq: PCRX) issues 2,200 inducement RSUs to two new employees - Stock Titan
Why Pacira BioSciences Inc. (82P) stock attracts wealthy investorsJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Pacira’s iovera° shows better outcomes than RFA for chronic back pain By Investing.com - Investing.com South Africa
Does Pacira’s ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira’s iovera° shows better outcomes than RFA for chronic back pain - Investing.com Nigeria
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain - Ortho Spine News
Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain - marketscreener.com
What macro factors could drive Pacira BioSciences Inc. (82P) stock higherWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
American Century Companies Inc. Has $28.26 Million Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock now2025 Price Action Summary & Weekly Sector Rotation Insights - BỘ NỘI VỤ
(PCRX) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation in Focus Following Moves to Defend EXPAREL Patents Against Generic Competition - Sahm
Pacira down after FDA filing for generic Exparel - MSN
Pacira BioSciences (PCRX): Assessing Valuation Following Legal Win That Delays EXPAREL Generic Approvals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire
Is Pacira’s 30-Month Generic Delay for EXPAREL Shifting the Investment Outlook for PCRX? - Sahm
Pacira BioSciences Inc. Files Patent Infringement Lawsuit, Initiating 30-Month Stay of ANDA Approvals for EXPAREL® - Quiver Quantitative
Pacira BioSciences files Exparel patent infringement lawsuits against the WhiteOak Group and Qilu Pharmaceutical - marketscreener.com
Pacira BioSciences Files EXPAREL® Patent Infringement - GlobeNewswire
What analysts say about Pacira BioSciences Inc 82P stockRetail Trading Trends & Learn the Basics of Investing in 5 Days - earlytimes.in
Is Pacira BioSciences Inc a good long term investmentRSI Overbought/Oversold & Low Entry Investment Ideas - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. (82P) stock beat Nasdaq index returnsWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Pacira BioSciences, Inc. $PCRX Shares Sold by Bank of Montreal Can - MarketBeat
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Is Pacira BioSciences Inc. (82P) stock attractive for dividend growth2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.48%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):